Skip to main content
. 2015 Dec 24;17:378. doi: 10.1186/s13075-015-0897-6

Fig. 3.

Fig. 3

Clinical developments according to C-reactive protein (CRP) status at baseline. Mean (95 % CI) developments in visual analog scale (VAS) global, VAS pain, EuroQ ol 5-Dimensions (EQ-5D) utility, and Evaluator’s global assessment of disease activity during 3 years of anti-TNF therapy in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), who had CRP elevation (CRP >3.0 mg/l) or did not have CRP elevation (CRP ≤3.0 mg/l) at baseline